Listen

Press releases

Receive e-mail alerts

Internal link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2017
August 16, 2017 at 11:00 AM UTC
Internal link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
July 05, 2017 at 11:00 AM UTC
Internal link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
June 15, 2017 at 11:04 AM UTC
Internal link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
June 13, 2017 at 11:00 AM UTC
Internal link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
June 08, 2017 at 01:03 PM UTC
Internal link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
May 31, 2017 at 11:00 AM UTC
Internal link ProQR Announces Results for the First Quarter of 2017
May 17, 2017 at 11:00 AM UTC
Internal link ProQR remembers co-founder Henri Termeer after his unexpected passing
May 15, 2017 at 11:00 AM UTC
Internal link ProQR Announces R&D Day in New York on June 15
May 09, 2017 at 11:00 AM UTC
Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 at 11:00 AM UTC
Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
April 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at the Deutsche Bank Health Care Conference
April 20, 2017 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 10, 2017 at 11:00 AM UTC
Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 at 11:00 AM UTC
Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Investor Conferences in March
March 01, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
February 28, 2017 at 12:00 PM UTC
Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
February 27, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference
February 07, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2016
November 14, 2016 at 12:00 PM UTC
Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients
October 27, 2016 at 11:00 AM UTC
Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC
September 27, 2016 at 11:00 AM UTC
Internal link ProQR to Present at Scientific and Investor Conferences in September
September 06, 2016 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2016
August 17, 2016 at 11:00 AM UTC

Press releases

Internal link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong

Internal link ProQR Announces Results for the Second Quarter of 2017

Internal link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Internal link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology

Internal link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference

Internal link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial

Internal link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

Internal link ProQR Announces Results for the First Quarter of 2017

Internal link ProQR remembers co-founder Henri Termeer after his unexpected passing

Internal link ProQR Announces R&D Day in New York on June 15

Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

Internal link ProQR to Present at the Deutsche Bank Health Care Conference

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU

Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

Internal link ProQR to Present at Two Upcoming Investor Conferences in March

Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference

Internal link ProQR Announces Results for the Third Quarter of 2016

Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

Internal link ProQR to Present at Scientific and Investor Conferences in September

Internal link ProQR Announces Results for the Second Quarter of 2016